Abstract:Human angiotensin-I-converting enzyme (ACE) is an important target of antihypertensive therapy, which possesses a bulky, hydrophobic pocket that is physicochemically compatible with a wide variety of peptide substrates and small-molecule ligands. Rational design of potent ACE inhibitors has long been an attractive topic in the chemical, biological and medical communities. In the present study, an integrative protocol is described to optimize and modify peptides bound with ACE based on their complex three-dimensional structures. The protocol combines a number of sophisticated computational methods including molecular dynamics (MD) simulation, quantitative structure-activity relationship (QSAR), molecular mechanics/Poisson-Boltzmann surface area (MM-PB/SA) and quantum mechanics/molecular mechanics (QM/MM) to discover new potent ACE-inhibitory peptides. With this strategy hundreds of potential peptides are generated virtually, from which several promising candidates are synthesized and assayed in vitro using a standard Fmoc-protected amino acid solid phase synthesis and spectrophotometric method, respectively. Six peptides are found to have potency against ACE, four of which (LVY, VLKP, MLPVY and LKIPLY) show satisfactory inhibitory capability (pIC(50)=5.84, 5.27, 5.40 and 5.57, respectively). Subsequently, the complex structures of tripeptide LVY and hexapeptide LKIPLY with ACE are computationally modeled and their binding free energies are estimated as -34.2 and -57.8 kcal/mol, respectively, by using a rigorous QM/MM scheme. Intensive steric collisions are observed around the C-terminus of peptide ligands in the bound state. Based upon the findings the C-terminal residues of the two peptides are modified to small, hydrophobic amino acids Val and Ala, resulting in mutated peptides LVA and LKIPVA, respectively. Consequently, a significant improvement in ACE inhibitory activity is observed for the LKIPVA mutant (pIC(50) increases from 5.57 to 6.07), whereas only a modest activity change was associated with the LVA mutant (pIC(50) decreases from 5.84 to 5.80).

Greener liquid-phase synthesis and the ACE inhibitory structure-activity relationship of an anti-SARS octapeptide.

TDPBP Derivative Aiding Liquid-Phase Synthesis Strategy and ACE Inhibitory Structure-activity Relationship of Anti-SARS Octapeptide

[Synthesis and Activity of ACE Inhibitory Peptides].

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Synthesis and Activity of an Octapeptide Inhibitor Designed for SARS Coronavirus Main Proteinase.

Novel Alkynylamide-Based Nonpeptidic Allosteric Inhibitors for SARS-CoV-2 3-Chymotrypsin-like Protease

Synthetic Peptides Outside the Spike Protein Heptad Repeat Regions As Potent Inhibitors of Sars-Associated Coronavirus

Integrating Computational Modeling and Experimental Assay to Discover New Potent Ace-Inhibitory Peptides

Molecular Modeling Studies of Peptide Drug Candidates Against SARS

Microwave-Assisted Solid-Phase Synthesis, Biological Evaluation and Molecular Docking of Angiotensin I-Converting Enzyme Inhibitors

The structure-based design of peptidomimetic inhibitors against SARS-CoV-2 3C like protease as Potent anti-viral drug candidate

Discovery of Unsymmetrical Aromatic Disulfides As Novel Inhibitors of SARS-CoV Main Protease: Chemical Synthesis, Biological Evaluation, Molecular Docking and 3D-QSAR Study

Structure-based Design, Synthesis, and Biological Evaluation of Peptidomimetic SARS-CoV 3clpro Inhibitors

Molecular modeling and chemical modification for finding peptide inhibitor against severe acute respiratory syndrome coronavirus main proteinase.

Highly Efficient Synthesis of Maleimide-braced Peptide Macrocycles and Their Potential Anti-SARS-CoV-2 Mechanisms

Optimisation and Characterisation of Novel Angiotensin-Converting Enzyme Inhibitory Peptides Prepared by Double Enzymatic Hydrolysis from Agaricus bisporus Scraps

Studies on the Bioactivities of ACE-inhibitory Peptides with Phenylalanine C-terminus Using 3D-QSAR, Molecular Docking and in Vitro Evaluation.

A Computer-Aided Approach for the Discovery of D-Peptides as Inhibitors of SARS-CoV-2 Main Protease

Synthesis and anti‐SARS‐CoV‐2 activity of amino acid modified cephalotaxine derivatives

Design and Synthesis of Peptidomimetic Severe Acute Respiratory Syndrome Chymotrypsin-Like Protease Inhibitors.

Biodirected Screening and Preparation of Larimichthys crocea Angiotensin-I-Converting Enzyme-Inhibitory Peptides by a Combined In Vitro and In Silico Approach